Tumor Immunology and Immunotherapy

Sunday, Nov. 17   

Monday, Nov. 18

Tuesday, Nov. 19

Wednesday, Nov. 20

Sunday, Nov. 17

Welcome and Keynote Lectures
5-7 p.m.

Updates in cell therapies
Crystal L. Mackall, Stanford University, Stanford, California

Story over time, discovery to translation, CTLA-4 and PD-1
Gordon J. Freeman, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening Reception
7-9 p.m.

Monday, Nov. 18 

Continental Breakfast
7-8 a.m.

Plenary Session 1: Intersection of Signaling Pathways and Immuno-Oncology
Session Chair: Stefani Spranger, MIT Koch Institute for Integrated Cancer Research, Cambridge, Massachusetts  
8-10 a.m.

STK11/LKB1 and other genomic drivers of a “cold” immune phenotype in NSCLC: Implications for precision immunotherapy
John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas

Impact on tumor-resident DC on anti-tumor immunity
Stefani Spranger

Targeting the RAS-MAPK pathway to enhance immune response
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Development of New Immune Therapy Combinations for Ovarian Cancer Using Genetically defined organoid platform*
Benjamin Neel, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York

Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo*
Bin-Jin Hwang, Duke University, Durham, North Carolina

10-10:30 a.m.

Plenary Session 2: Novel Cell Therapies
Session Chair: Katayoun Rezvani, The University of Texas MD Anderson Cancer Center, Houston, Texas   
10:30 a.m.-12:30 p.m.

Optimizing T cell receptor gene therapy for cancer
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, Washington

Engineering natural killer cells for the treatment of cancer
Katayoun Rezvani

Understanding resistance to develop next-generation CART for lymphoid malignancies
Marco Ruella, University of Pennsylvania, Philadelphia, Pennsylvania

Development of a transcriptomic T-cell atlas highlights the differential role of T-cell subpopulations in CAR T-cell therapy resistance*
Gregory Chen, University of Pennsylvania, Philadelphia, Pennsylvania

Modulation of integrin CD11b as a novel therapeutic strategy against lung cancer*
Terese Geraghty, Rush University, Chicago, Illinois

Poster Session A / Lunch
12:30-3 p.m.

Plenary Session 3: Adverse Events
Session Chair: Antony Rosen, Johns Hopkins University, Baltimore, Maryland  
3-5 p.m.

Checkpoint inhibitor induced autoimmune diabetes and endocrine syndromes
Kevan Herold, Yale School of Medicine, New Haven, Connecticut 

Immune checkpoint inhibitor-associated cardiotoxicities: Learning from mice and humans
Javid J. Moslehi, Vanderbilt University School of Medicine, Nashville, Tennessee 

Autoimmune rheumatic diseases and cancer: An example of natural cancer immunoediting?
Antony Rosen

Investigating the mechanisms of immune-related adverse events using engineered animal models*
Nikhil Joshi, Yale University, New Haven, Connecticut

Evening on Own
5 p.m.

Tuesday, Nov. 19

Continental Breakfast
7-8 a.m.

Plenary Session 4: Epigenomics of Immuno-Oncology 
Session Chair: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Maryland
8-10 a.m.

Epigenetic therapy – potential efficacy for enhancing immune checkpoint therapy
Stephen B. Baylin

Reprogramming the epigenome for enhancing CAR T cell anti-tumor Efficacy
Joseph A. Fraietta, University of Pennsylvania, Philadelphia, Pennsylvania

Molecular programs defining tumor-specific T cell dysfunction and reprogrammability
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York

Disrupting enhancers within the core epigenetic program of exhaustion improves T-cell responses and enhances tumor control*
Debattama Sen, Dana-Farber Cancer Institute, Boston, Massachusetts

Epigenetic deregulation in LSD1-deficient luminal mammary tumor cells leads to their increased metastasis via reprogramming of the immune microenvironment*
Zhe Li, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

10-10:30 a.m.

Plenary Session 5: Imaging and New Technologies  
Session Chair: Mohammad Rashidian, Harvard Medical School, Cambridge, Massachusetts
10:30 a.m.-12:30 p.m.

Noninvasive imaging of immune responses
Mohammad Rashidian

Whole body PD-L1 and PD-1 PET: First in human experience
David Leung, Bristol-Myers Squibb, Princeton, New Jersey

AI-powered pathology for precision medicine
Andrew H. Beck, PathAI, Boston, Massachusetts

Irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic antitumor immunity*
Irving Allen, Virginia Tech, Blacksburg, Virginia

Lunch on Own
12:30-2:30 p.m.

Plenary Session 6: Tumor Evolution, Tumor Heterogeneity, and Tumor Microenvironment
Session Chair: Christina Leslie, Memorial Sloan Kettering Cancer Center, New York, New York 
2:30-4:30 p.m.

Revealing the role of nonsense mediated decay in anti-tumour immunogenicity
Samra Turajlic, The Francis Crick Institute, London, United Kingdom

Myeloid cell control of tumor immunity
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

Chromatin state and scRNA-seq analysis defines a common differentiation trajectory towards T cell exhaustion
Christina Leslie

Loss of PD-1 promotes antitumor immunity by improving functions of both PD-1+ and PD-1- CD8+ T cells in the tumor microenvironment*
Kristen Pauken, Harvard Medical School, Boston, Massachusetts

Active and quiescent tertiary lymphoid structures, differentiated using FOXP1 expression, play a role in immunity to breast cancer*
Pushpamali De Silva, Institut Jules Bordet, Brussels, Belgium

Poster Session B / Reception
4:30-7 p.m.

Wednesday, Nov. 20

Continental Breakfast
7-8 a.m.

Plenary Session 7: Interaction Between the Microbiome and Immunity, Systemic and Local Responses  
Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-10 a.m.

The microbiota and colorectal cancer
Wendy S. Garrett, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

The unsuspected role of gut microbiota in cancer therapies: antigen mimicry between intestinal phage and tumor antigens
Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France

The role of the gut microbiome in response and toxicity to cancer therapy
Jennifer A. Wargo

10-10:30 a.m.

Plenary Session 8: Interface of Genetics, Antigens, and Immuno-Oncology, Including Vaccines, Adjuvants, and Biomarkers
Session Chair: Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, New York 
10:30 a.m.-12:30 p.m.

T cells as a drug for the personalized immunotherapy of cancer
Steven A. Rosenberg, National Cancer Institute, Bethesda, Maryland

Tumor intrinsic drivers of response and resistance to checkpoint blockade in MRD tumors
Luis A. Diaz

Antigen dominance hierarchies shape tumor T cell phenotypes and immunotherapy responses*
Megan Burger, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

Genomic landscape of immunotherapy resistance in lung cancer*
Denise Lau, Tempus, Chicago, Illinois

Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination*
Joseph Antonios, Yale School of Medicine, New Haven, Connecticut

Emergence of quality metrics for neoantigens: Dissimilarity to the self-proteome as a novel determinant of immunogenicity*
Lee Richman, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Closing Remarks and Departure
12:30 a.m.

*Short talk from proffered abstract

Top of page